The Tumor Microenvironment: How Cancer Evades the Immune System
In our previous post, we explored how the immune system recognizes abnormal cells and launches an attack against cancer. But recognizing a cancer cell is only part of the process. Immune cells must also reach the tumor, remain active, and overcome the signals that cancer uses to protect itself.
One important factor influencing this process is the tumor microenvironment (TME): the complex community of cells, molecules, and structures surrounding a tumor.
Understanding the TME helps explain why cancer can sometimes survive despite an active immune response—and why researchers are investigating treatments that target not only cancer cells, but also the environment that supports them.
What Is the TME?
A tumor is more than a collection of cancer cells. It exists within a surrounding environment containing different components, each of which can influence how the tumor grows and interacts with the immune system.
These include:
Cancer cells: The abnormal cells that form the tumor and influence their surroundings by releasing signaling molecules.
Immune cells: Including T cells, macrophages, and other immune cells that may attack cancer, support inflammation, or suppress immune activity.
Cancer-associated fibroblasts (CAFs): Cells that produce structural proteins and signaling molecules, helping shape the tissue around a tumor.
Blood vessels: Structures that supply oxygen and nutrients and influence how immune cells enter tumor tissue.
Extracellular matrix (ECM): A network of proteins and other molecules that provides structural support but can also restrict cell movement.
Signaling molecules: Chemical messengers that affect the behavior of cancer cells and the immune cells around them.
How Does the TME Help Cancer Evade the Immune System?
Cancer can influence its surroundings in several ways. Although the exact mechanisms differ between tumor types and individual patients, four important features help explain how the TME can interfere with immune activity.
1. Suppressive Immune Cells
Some tumors accumulate regulatory T cells (Tregs) and certain populations of tumor-associated macrophages (TAMs) that can suppress immune responses. These cells may release inhibitory signals, alter the activity of nearby immune cells, and create conditions that favor tumor survival. This can reduce the effectiveness of cytotoxic T cells, particularly CD8+ T cells, which are important for killing abnormal cells. The presence of immune cells within a tumor, therefore, does not automatically mean that the immune response is strong or effective. Researchers must also understand what those cells are doing.
2. Physical Barriers Around the Tumor
Cancer-associated fibroblasts (CAFs) can produce extracellular matrix components that change the structure and density of the tissue surrounding a tumor. In some cancers, this creates a dense stromal environment that makes it more difficult for T cells to enter or move through tumor tissue. This concept is one reason researchers study immune-excluded tumors (tumors in which immune cells are present around the tumor but have limited access to cancer cells themselves.) However, stromal tissue is not always harmful. Its effects depend on the types of cells present, their organization, and the specific tumor context.
3. Signals That Weaken Immune Activity
Cells communicate through chemical signals, including cytokines and growth factors. Within the TME, these signals can influence whether immune cells become activated, remain functional, or become suppressed.
For example:
TGF-β can suppress aspects of T-cell function and promote stromal changes.
IL-10 can limit certain inflammatory and immune responses.
VEGF promotes blood vessel formation and can also interfere with effective antitumor immunity.
The effects of these molecules depend on their concentration, location, and the cells responding to them. When the balance of signals favors immune suppression, cancer cells may become harder for the immune system to eliminate.
4. Low Oxygen and Metabolic Stress
Solid tumors often contain regions where oxygen and nutrients are limited. This condition, called hypoxia, can arise when tumor growth outpaces the development of an adequate blood supply. Low oxygen and competition for nutrients can change how immune cells function. Metabolic byproducts, including lactate in some tumor environments, may further interfere with immune activity. As a result, T cells can struggle to maintain the energy and function needed for an effective response.
Why Does the Tumor Microenvironment Matter for Cancer Treatment?
Understanding the TME helps researchers investigate why some tumors respond to immunotherapy while others show limited responses.
For example, immune checkpoint inhibitors target pathways that restrain immune activity. These treatments can help restore antitumor responses in some patients, but they do not eliminate every barrier within a tumor. If immune cells cannot adequately reach cancer cells, or if other suppressive mechanisms remain active, treatment may still be less effective.
Researchers are therefore studying strategies that combine different approaches, such as modifying suppressive signals, targeting selected stromal mechanisms, or improving the ability of immune cells to enter and function within tumors.
This is also an important challenge for CAR-T cell therapy, in which a patient's T cells are engineered to recognize a chosen cancer-associated target. Even when engineered T cells can recognize their intended target, they must still reach cancer cells and function within the tumor environment. These challenges are particularly important in solid tumors.
Looking at Cancer in Its Spatial Context
One growing area of cancer research is spatial transcriptomics, which allows scientists to study gene activity while preserving information about where cells are located within tissue.
Rather than asking only which cell types are present in a tumor, researchers can investigate questions such as:
Are T cells located inside tumor regions or mainly around their edges?
Do fibroblast-rich areas coincide with reduced immune-cell access?
Where are macrophages and other immune populations concentrated?
How do neighboring cells and local tissue conditions differ across a tumor?
These questions matter because two tumors may contain similar cell types but arrange them very differently. Their spatial organization may help researchers understand differences in immune activity and treatment response.
Spatial studies can reveal patterns and associations, although they do not automatically prove that a particular cell arrangement causes treatment resistance.
Conclusion
Effective cancer treatment may depend not only on targeting the tumor itself, but also on understanding the environment in which it grows.
However, if the TME can help cancer evade the immune system, could changing that environment make existing immunotherapies more effective?
In our next post, we’ll explore one approach to this challenge: CAR-T cell therapy, which engineers T cells to recognize and attack cancer.
Comments